Mitochondria-directed therapeutics

Antioxidants and Redox Signaling

Volumn 10, Issue 3, 2008, Pages 575-578

  Armstrong, Jeffrey S ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DECYLUBIQUINONE; GLUTATHIONE; MANGANES 5,10,15,20 TETRAKIS(4 BENZOIC ACID)PORPHYRIN; MITOFUSIN 2; PROTEIN MITOQ; REACTIVE OXYGEN METABOLITE; SZETO SCHILLER PEPTIDE DERIVATIVE; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFLAMMATION; ISCHEMIA; LIVER DISEASE; MITOCHONDRION; MOLECULAR DYNAMICS; NECROSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; ELECTRON TRANSPORT; HUMANS; MITOCHONDRIA; NECROSIS; SIGNAL TRANSDUCTION; THERAPEUTICS;

EID: 38349057828     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1929     Document Type: Review

References (42)

1. Ackermann EJ, Taylor JK, Narayana R, and Bennett CF. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J Biol Chem 274: 11245-11252, 1999.
2. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, and Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19: 1088-1095, 2005.
3. Armstrong JS and Jones DP. Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. FASEB J 16: 1263-1265, 2002.
4. Armstrong JS, Whiteman M, Rose P, and Jones DP. The coenzyme Q10 analog decylubiquinone inhibits the activation of the redox-dependent mitochondrial permeability transition: role of cytochrome bc1. J Biol Chem 278: 49079-49084, 2003.
5. Armstrong JS. The role of the mitochondrial permeability transition in cell death. Mitochondrion 6: 225-234, 2006.
6. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 147:239-248, 2006.
7. Armstrong JS. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 151 :1154-1165, 2007.
8. Bell EL, Klimova T, and Chandel NS. Targeting the mitochondria for cancer therapy: regulation of hypoxia-inducible factor by mitochondria. Antioxid Redox Signal 10: 635-640, 2008.
9. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR, and Chandel NS. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 177: 1029-1036, 2007.
10. Bernardi P, Krauskopf A, Basso E, Petronilli V, Blalchy-Dyson E, Di LF, and Forte MA. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J 273: 2077-2099, 2006.
11. Burwell LS and Brookes PS. Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid Redox Signal 10: 579-599, 2008.
12. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP, and Tang J. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 6: 872-883, 2004.
13. Collombet JM and Coutelle C. Towards gene therapy of mitochondrial disorders. Mol Med Today 4: 31-38, 1998.
14. D'Souza GG and Weissig V. Approaches to mitochondrial gene therapy. Curr Gene Ther 4: 317-328, 2004.
15. Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko GV, Rudka T, Bartoli D, Polishuck RS, Danial NN, De Strooper B and Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126: 177-189, 2006.
16. Gottlieb E. OPA1 and PARL keep a lid on apoptosis. Cell 126: 27-29, 2006.
17. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1: 401-408, 2005.
18. Halliwell B and Gutteridge JM. Free Radicals in Biology and Medicine. Oxford, UK: Oxford University Press, 1999.
19. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans 34: 232-237, 2006.
20. Karbowski M and Youle RJ. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ 10: 870-880, 2003.
21. Lawrence JW, Claire DC, Weissig V, and Rowe TC. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 50: 1178-1188, 1996.
22. Li L, Thomas RM, Suzuki H, Brabander JK, Wang X, and Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305: 1471-1474, 2004.
23. Lin MT and Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795, 2006.
24. Liu X, Kim CN, Yang J, Jemmerson R, and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86: 147-157, 1996.
25. Lu C and Armstrong JS. Role of calcium and cyclophilin D in the regulation of mitochondrial permeabilization induced by glutathione depletion. Biochem Biophys Res Comm 363: 572-577, 2007.
26. Lu C, Zhang D, Whiteman M, and Armstrong JS. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA? Antioxid Redox Signal 10: 651-660, 2008.
27. Martins de Brito O and Scorrano L. Mitofusin 2: a mitochondriashaping protein with signaling roles beyond fusion. Antioxid Redox Signal 10: 621-633, 2008.
28. Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, Huffman K, Wallace DC, and Malfroy B. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J Neurosci 21: 8348-8353, 2001.
29. Mitchell P and Moyle J. Chemiosmotic hypothesis of oxidative phosphorylation. Nature 213: 137-139, 1967.
30. Murphy MP and Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47: 629-656, 2007.
31. Neuspiel M, Zunino R, Gangaraju S, Rippstein P, and McBride H. Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization. J Biol Chem 280: 25060-25070, 2005.
32. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, and Beal MF. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98: 1141-1148, 2006.
33. Scaffidi C, Fulda S, Srinivasan A, Friesen C, and Li F. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687, 1998.
34. Schon EA and DiMauro S. Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr Med Chem 10: 2523-2533, 2003.
35. Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 8: E277-E283, 2006.
36. Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal 10: 601-619, 2008.
37. Walensky LD, Kung AL, Escher I, Malia TJ, Barbauto S, Wright RD, Wagner G, Verdine GL, and Korsmeyer SJ. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305: 1466-1470, 2004.
38. Whiteman M, Rose P, Siau JL, Cheung NS, Tan GS, Halliwell B, and Armstrong JS. HOCl-mediated mitochondrial dysfunction and apoptosis in human hepatoma Hepg2 and human fetal liver cells: role of mitochondrial permeability transition. Free Rad Biol Med 38: 1571-1584, 2005.
39. Whiteman M, Spencer JPE, Szeto HH, and Armstrong JS. Do mitochondriotropic antioxidants prevent chlorinative stress-induced mitochondrial and cellular injury? Antioxid Redox Signal 10: 641-650, 2008.
40. Yu T, Robotham JL, and Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA 103: 2653-2658, 2006.
41. Zeviani M and Carelli V. Mitochondrial disorders. Curr Opin Neurol 16: 585-594, 2003.
42. Zamzami N, Marzo I, Susin SA, Brenner C, Larochette N, Marchetti P, Reed J, Kofler R, and Kroemer G. The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Oncogene 16: 1055-1063, 1998.